Volume 5, Issue 1, March 2019, Page: 1-4
Streamlining the Workflow of Stereotactic Radiosurgery (SRS) on Tomotherapy: Experience from a Tertiary Care Centre from India
Vijay Palwe, Department of Radiation Oncology, HCG Manavata Cancer Centre, Nashik, India
Prakash Pandit, Department of Radiation Oncology, HCG Manavata Cancer Centre, Nashik, India
Rajnish Nagarkar, Department of Surgical Oncology, HCG Manavata Cancer Centre, Nashik, India
Received: Feb. 18, 2019;       Accepted: Mar. 30, 2019;       Published: Jun. 4, 2019
DOI: 10.11648/j.rst.20190501.11      View  237      Downloads  41
Abstract
Brain metastasis has become a major concern in the oncology fraternity. The use of conventional treatment approaches such as single-fraction stereotactic radiosurgery (SRS), hypofractionated stereotactic radiotherapy (SRT), or whole-brain radiotherapy (WBRT) has been widely explored. Stereotactic radiosurgery (SRS) has been widely used and known for its high efficiency and low toxicity. SRS on tomotherapy has emerged as a promising treatment approach at our centre. In the advent of multidisciplinary care, developing and implementing targeted treatment approaches for cancer patients, SRS has proven to be highly effective and efficient. We report our first experience of brain metastases in a known case of breast cancer treated with SRS on tomotherapy in a tertiary cancer centre in India.
Keywords
Stereotactic Radiotherapy, Tomotherapy, Brain Metastasis, Stereotactic Radiosurgery Component
To cite this article
Vijay Palwe, Prakash Pandit, Rajnish Nagarkar, Streamlining the Workflow of Stereotactic Radiosurgery (SRS) on Tomotherapy: Experience from a Tertiary Care Centre from India, Radiation Science and Technology. Vol. 5, No. 1, 2019, pp. 1-4. doi: 10.11648/j.rst.20190501.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Nagai A, Shibamoto Y, Yoshida M, Wakamatsu K, Kikuchi Y. Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy. Int J Mol Sci. 2014; 15 (4): 6910-24. Published 2014 Apr 22. doi: 10.3390/ijms15046910.
[2]
Vellayappan BA, Doody J, Vandervoort E, et al. Pre-operative versus post-operative radiosurgery for brain metastasis: Effects on treatment volume and inter-observer variability. J Radiosurg SBRT. 2018; 5 (2): 89-97.
[3]
Soffietti R1, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, Krauseneck P, Marosi C, Siegal T, Vecht C. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006 Jul; 13 (7): 674-81.
[4]
Märtens B, Janssen S, Werner M, et al. Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach. BMC Cancer. 2012; 12: 497. doi: 10.1186/1471-2407-12-497.
[5]
Nieder C; Grosu AL; Gaspar LE. Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat Oncol 9: 155; 2014.
[6]
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1; 37 (4): 745-51.
[7]
Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980 Jan; 6 (1): 1-9.
[8]
Khan A; Dicker A. On the merits and limitations of whole brain therapy. JCO 31: 11-13; 2013.
[9]
Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Shaw P, Beyene J, Chang EL. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015 Mar 15; 91 (4): 710-7.
[10]
Zeng M, Han LF. Stereotactic radiosurgery: a "targeted" therapy for cancer. Chin J Cancer. 2012; 31 (10): 471-5.
[11]
Cohen-Inbar O, Sheehan JP. The role of stereotactic radiosurgery and whole brain radiation therapy as primary treatment in the treatment of patients with brain oligometastases - A systematic review. J Radiosurg SBRT. 2016; 4 (2): 79-88.
[12]
Yaeh A, Nanda T, Jani A, Rozenblat T, Qureshi Y, Saad S, Lesser J, Lassman AB, Isaacson SR, Sisti MB, Bruce JN, McKhann GM 2nd, Wang TJ. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neurooncol. 2015 Sep; 124 (3): 507-14. doi: 10.1007/s11060-015-1871-5.
[13]
Soffietti R, Rudā R, Mutani R. Management of brain metastases. J Neurol. 2002 Oct; 249 (10): 1357-69.
[14]
Kirova YM, Chargari C, Zefkili S, Campana F. Could helical tomotherapy do whole brain radiotherapy and radiosurgery?. World J Radiol. 2010; 2 (4): 148-50.
[15]
Soisson ET, Hoban PW, Kammeyer T, et al. A technique for stereotactic radiosurgery treatment planning with helical tomotherapy. Med Dosim. 2011; 36 (1): 46-56.
Browse journals by subject